Long-term survival of a child with refractory anaplastic large cell lymphoma following therapy with an antisense oligonucleotide, topotecan, and vinblastine
Corresponding Author
Grazyna Wrobel
Department of Bone Marrow Transplantation, Children Oncology and Haematology, Medical University of Wroclaw, Wroclaw, Poland
Correspondence to: Grazyna Wrobel, Department of Bone Marrow Transplantation, Children Oncology and Haematology, 50–345 Wroclaw, 44 Bujwida St, Wroclaw, Poland
E-mail: [email protected]
Search for more papers by this authorRadosław Chaber
Department of Bone Marrow Transplantation, Children Oncology and Haematology, Medical University of Wroclaw, Wroclaw, Poland
Search for more papers by this authorJolanta Rygier
Cytogenetics Laboratory, Maria-Sklodowska Memory Cancer Center and Institute of Oncology, Warsaw, Poland
Search for more papers by this authorJolanta Bonar
Department of Bone Marrow Transplantation, Children Oncology and Haematology, Medical University of Wroclaw, Wroclaw, Poland
Search for more papers by this authorKatarzyna Muszynska-Roslan
Department of Paediatric Oncology and Haematology, Medical University of Bialystok, Bialystok, Poland
Search for more papers by this authorAlicja Chybicka
Department of Bone Marrow Transplantation, Children Oncology and Haematology, Medical University of Wroclaw, Wroclaw, Poland
Search for more papers by this authorCorresponding Author
Grazyna Wrobel
Department of Bone Marrow Transplantation, Children Oncology and Haematology, Medical University of Wroclaw, Wroclaw, Poland
Correspondence to: Grazyna Wrobel, Department of Bone Marrow Transplantation, Children Oncology and Haematology, 50–345 Wroclaw, 44 Bujwida St, Wroclaw, Poland
E-mail: [email protected]
Search for more papers by this authorRadosław Chaber
Department of Bone Marrow Transplantation, Children Oncology and Haematology, Medical University of Wroclaw, Wroclaw, Poland
Search for more papers by this authorJolanta Rygier
Cytogenetics Laboratory, Maria-Sklodowska Memory Cancer Center and Institute of Oncology, Warsaw, Poland
Search for more papers by this authorJolanta Bonar
Department of Bone Marrow Transplantation, Children Oncology and Haematology, Medical University of Wroclaw, Wroclaw, Poland
Search for more papers by this authorKatarzyna Muszynska-Roslan
Department of Paediatric Oncology and Haematology, Medical University of Bialystok, Bialystok, Poland
Search for more papers by this authorAlicja Chybicka
Department of Bone Marrow Transplantation, Children Oncology and Haematology, Medical University of Wroclaw, Wroclaw, Poland
Search for more papers by this authorStatement of prior presentation: This work was reported in part in poster form at the III World Asthma & COPD Forum and the World Forum of Pediatrics, Dubai, UAE, 24–27 April 2010.
Abstract
Anaplastic large cell lymphoma includes a subset of highly aggressive tumours and has a relapse rate of 30% at 2 years. Relapsed patients often have poor clinical outcome. The use of antisense oligonucleotides to down-regulate Bcl-2 protein can reverse chemotherapy resistance. The authors describe an 11-year-old boy with recurrent anaplastic large cell lymphoma who had received double high-dose chemotherapy followed by autologous haematopoietic stem-cell transplantation, had refractory disease and then had achieved long-term remission with the use of an antisense oligonucleotides in combination with vinblastine and topotecan. Copyright © 2011 John Wiley & Sons, Ltd.
References
- 1 Reed JC. Bcl-2-family proteins and hematologic malignancies: history and future prospects. Blood 2008; 111: 3322–3330.
- 2 Dias N, Stein CA. Potential role of antisense oligonucleotides in cancer therapy. The example of Bcl-2 antisense oligonucleotides. Eur J Pharm Biopharm 2002; 54: 263–269.
- 3 Marzo J, Naval J. Bcl-2 family members as molecular targets in cancer therapy. Biochem Pharmacol 2008; 76: 939–946.
- 4 Kramer MH, Hermans J, Parker J, et al. Clinical significance of Bcl-2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 1996; 14: 2131–2138.
- 5 Cotter FE, Waters J, Cunningham D. Human Bcl-2 antisense therapy for lymphomas. Biochim Biophys Acta 1999; 1489: 97–106.
- 6 Webb A, Cunningham D, Cotter F, et al. BCL-2 antisense therapy in patients with non Hodgkin lymphoma. Lancet 1997; 349: 1137–1141.
- 7 Waters JS, Webb A, Cunningham D, et al. Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2000; 18: 1812–23.
- 8 Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 1980; 7: 332–339.
- 9 Seidemann K, Tiemann M, Schrappe M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin–Frankfurt–Munster Group Trial NHL-BFM 90. Blood 2001; 97: 3699–3706.
- 10 Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2 0.1998. DCTD, NCI, NIH, DHHS. In Edition, 1998.
- 11 Brugières L, Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol 2009; 27: 897–903.
- 12 Woessmann W, Peters C, Lenhard M, et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents—a Berlin–Frankfurt–Munster group report. Br J Haematol 2006; 133: 176–182.
- 13 ten Berge RL, Meijer CJLM, Dukers DF, et al. Expression levels of apoptosis-related proteins predict clinical outcome in anaplastic large cell lymphoma. Blood 2002; 99: 4540–4546.
- 14 Marcucci G, Byrd JC, Dai G, et al. Phase I and pharmacodynamics studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 2003; 101: 425–431.
- 15 Rheingold SR, Hogarty MD, Blaney SM, et al. Children's Oncology Group Study. Phase I trial of G3139, a Bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed soilid tumors: a children's oncology group study. J Clin Oncol 2007; 25: 1512–1518.
- 16 Kim R, Emi M, Tanabe K, Toge T. Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer 2004; 101: 2491–2502.
- 17 O'Brien S, Moore JO, Boyd TE, et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J Clin Oncol 2009; 27: 5208–5212.
- 18 Pro B, Leber B, Smith M, et al. Phase III multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma. Br J Haematol 2008; 143: 355–360.
- 19 Younes A, Preti HA, Hagemeister FB, et al. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Ann Oncol 2001: 12: 923–927.
- 20 Voloschin AD, Betensky R, Wen PY, Hochberg F, Batchelor T. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol 2008; 86: 211–215
- 21 Brugières L, Quartier P, Le Deley MC, et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children—a report from the French Society of Pediatric Oncology. Ann Oncol 2000; 11: 53–58.
